Hostname: page-component-78c5997874-4rdpn Total loading time: 0 Render date: 2024-11-14T04:24:15.977Z Has data issue: false hasContentIssue false
  • English
  • Français

Quinolone Use as a Risk Factor for Nosocomial Clostridium difficile-Associated Diarrhea

Published online by Cambridge University Press:  02 January 2015

Clarwyn Yip ,
Mark Loeb ,
Suzette Salama ,
Lorraine Moss  and
Jan Olde
Clarwyn Yip
Affiliation:
Department of Medicine, McMaster University, Hamilton, Ontario, Canada
Mark Loeb*
Affiliation:
Department of Pathology and Molecular Medicine, McMaster University, Hamilton, Ontario, Canada Hamilton Civics Hospital, Hamilton, Ontario, Canada
Suzette Salama
Affiliation:
Department of Medicine, McMaster University, Hamilton, Ontario, Canada
Lorraine Moss
Affiliation:
Department of Pathology and Molecular Medicine, McMaster University, Hamilton, Ontario, Canada
Jan Olde
Affiliation:
Hamilton Civics Hospital, Hamilton, Ontario, Canada
*
Hamilton Health Sciences Corporation, 711 Concession St, Hamilton, Ontario L8V1C3, Canada
Get access Rights & Permissions [Opens in a new window]

Abstract

Objective:

To determine modifiable risk factors for nosocomial Clostridium difficile-associated diarrhea (CDAD).

Design:

Case-control study.

Setting:

300-bed tertiary-care hospital.

Participants:

Hospital inpatients present during the 3-month study period.

Methods:

Case-patients identified with nosocomial CDAD over the study period were compared to two sets of control patients: inpatients matched by age, gender, and date of admission; and inpatients matched by duration of hospital stay. Variables including demographic data, comorbid illnesses, antibiotic exposure, and use of gastrointestinal medications were assessed for case- and control-patients. Conditional logistic regression was performed to identify risk factors for nosocomial CDAD.

Results:

27 case-patients were identified and were compared to the two sets of controls (1:1 match for each comparison set). For the first set of controls, use of ciprofloxacin (odds ratio [OR], 5.5; 95% confidence interval [CI95], 1.2-24.8; P=.03) was the only variable that remained significant in the multivariable model. For the second set of controls, prior exposure to cephalosporins (OR, 6.7; CL,5, 1.3-33.7; P=.02) and to ciprofloxacin (OR, 9.5; CI95, 1.01-88.4; P=.05) were kept in the final model.

Conclusions:

Along with cephalosporins, prior quinolone use predisposed hospitalized patients to nosocomial CDAD. Quinolones should be used judiciously in acute-care hospitals, particularly in those where CDAD is endemic.

Type
Original Articles
Information
Infection Control & Hospital Epidemiology , Volume 22 , Issue 9 , September 2001 , pp. 572 - 575
Copyright
Copyright © The Society for Healthcare Epidemiology of America 2001

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1.Johnson, S, Gerding, DN. Clostridium difficile-associated diarrhea. Clin Infect Dis 1998;26:1027–1036.Google Scholar
2.Spencer, RC. Clinical impact and associated costs of Clostridium difficile-associated disease. J Antimicrob Chemother 1998;41(suppl):C5–C12.Google Scholar
3.Wilcox, M, Cunniffe, JG, Trundle, C, Redpath, C. Financial burden of hospital-acquired Clostridium difficile infection. J Hosp Infect 1996;34:23–30.CrossRefGoogle ScholarPubMed
4.Schuller, I, Saha, V, Kingston, J, Eden, T, Tabaqchali, S. Investigation and management of Clostridium difficile colonization in a paediatric oncology unit. Arch Dis Child 1995;72:219–222.CrossRefGoogle Scholar
5.Emoto, M, Kawarabayashi, T, Hachisuga, T, Eguchi, F, Shirakawa, K. Clostridium difficile colitis associated with cisplatin-based chemotherapy in ovarian cancer patients. Gynecol Oncol 1996;61:369–372.CrossRefGoogle ScholarPubMed
6.Bliss, DZ, Johnson, S, Savik, K, Clabots, CR, Willard, K, Gerding, DN. Acquisition of Clostridium difficile and Clostridium difficile-associated diarrhea in hospitalized patients receiving tube feeding. Ann Intern Med 1998;129:1012–1019.Google Scholar
7.Brown, E, Talbot, GH, Axelrod, P, Provencher, M, Hoegg, C. Risk factors for Clostridium difficile toxin-associated diarrhea. Infect Control Hosp Epidemiol 1990;11:283–290.CrossRefGoogle ScholarPubMed
8.Aronsson, B, Molby, R, Nord, CE. Antimicrobial agents and Clostridium difficile in acute enteric disease: epidemiological data from Sweden, 1980-82. J Infect Dis 1985;151:476–481.Google Scholar
9.Impallomeni, M, Galletlt, NP, Wort, SJ, Starr, JM, Rogers, TR. Increased risk of diarrhea caused by Clostridium difficile in elderly patients receiving cefotaxime. BMJ 1995;311:1345–1346.CrossRefGoogle ScholarPubMed
10.Delmee, M, Avesani, V. Comparative in vitro activity of seven quinolones against 100 clinical isolates of Clostridium difficile. Antimicrob Agents Chemother 1986;29:374–375.CrossRefGoogle ScholarPubMed
11.Chow, AW, Cheng, N, Bartlett, KH. In vitro susceptibility of Clostridium difficile to new beta-lactam and quinolone antibiotics. Antimicrob Agents Chemother 1985;28;842–844.Google Scholar
12.McFarland, LV, Bauwens, JE, Melcher, SA, Surawicz, CM, Greenberg, RN, Elmer, GW. Ciprofloxacin-associated Clostridium difficile disease. Lancet 1995;346:977–978.Google Scholar
13.Bates, CJ, Wilcox, MH, Spencer, RC, Harris, DM. Ciprofloxacin and Clostridium difficile infection. Lancet 1990;336:1193.CrossRefGoogle ScholarPubMed
14.Cain, DB, O'Connor, ME. Pseudomembranous colitis associated with ciprofloxacin. Lancet 1990;336:946.Google Scholar
15.Ehrenpreis, ED, Iievens, MW, Craig, RM. Clostridium difficile-associated diarrhea after norfloxacin. J Clin Gastroenterol 1990;12:188–189.CrossRefGoogle ScholarPubMed